3C
AMPH icon

361 Capital’s Amphastar Pharmaceuticals AMPH Stock Holding History

361 Capital’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		$822K Buy
+36,614
New +$671K 0.39% 104

Other funds holding AMPH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Nordea Investment Management
Nordea Investment Management Stockholm, Sweden $107B AUM 24.58% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

361 Capital's AMPH Position: Q2 2020 in Review

361 Capital opened a new position in Amphastar Pharmaceuticals (AMPH) in Q2 2020: 36,614 shares worth $822K. The stake represents 0.39% of the portfolio and ranks #104 among its holdings.

135 funds tracked by Wall St. Rank hold AMPH as of Q2 2020.

  • 361 Capital held 36,614 shares of Amphastar Pharmaceuticals worth $822K as of Q2 2020.
  • Amphastar Pharmaceuticals was a new 361 Capital position in Q2 2020.
  • Amphastar Pharmaceuticals made up 0.39% of 361 Capital's portfolio in Q2 2020, its #104 holding.
  • 135 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q2 2020.

Based on 361 Capital's 13F filing for Q2 2020, filed 14 Aug 2020.